Analysis of the curative effect of Lipo-prostaglandin E1 on non-ST segment elevation myocardial infarction
10.3760/cma.j.issn.0254-9026.2010.08.006
- VernacularTitle:前列腺素E1脂微球载体制剂治疗非ST段抬高心肌梗死的疗效分析
- Author:
Xiaobin WANG
;
Li ZHU
;
Yigang YIN
;
Ruzhu WANG
;
Yin REN
;
Ming CHEN
;
Jianmin LI
;
Linlin GAO
- Publication Type:Journal Article
- Keywords:
Prostaglandin E1;
Myocardial infarction
- From:
Chinese Journal of Geriatrics
2010;29(8):635-637
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of Lipo-prostaglandin E1 (LipoPGE1) in the treatment of non-ST segment elevation acute myocardial infarction (NSTEAMI).Methods A total of 86 patients with NSTEAMI were randomly and equally divided into LipoPGE1 group (n= 43) which received intravenous LipoPGE1 combined with low-molecular-weight heparin,aspirin, clopidogrel and other basic therapy, and the control group (n=43) which received placebo combined with the same therapy. The basic clinical settings, curative effect, main adverse cardiovascular events (MACEs) within 30 days including sudden death, new-onset myocardial infarction and target vessel revascularization, bleeding complications and drug adverse effects were observed. Results There were no significant differences in basic clinical characteristics between the two groups. Compared with control group, the patients in LipoPGE1 group showed. significant improvements of ECG (93.0% vs. 74.4%), angina (95.3% vs. 81.4%, both P＜0. 05), the incidences of left heart failure (2.3% vs. 14.0%) and MACEs within 30 days (4.7% vs.18.6%)(both P＜0.05). There were no serious drug adverse effects. Conclusions The LipoPGE1 combined with heparin, aspirin and clopidogrel is effective and safe in the treatment of NSTEAMI,which could improve the clinical symptoms, distal myocardium perfusion and cardiac function,decrease the incidence of MACEs.
